NEW YORK, NY / ACCESSWIRE / March 10, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Shattuck Labs, Inc. (NASDAQ:STTK)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/shattuck-labs-inc-loss-submission-form?prid=24562&wire=1
Lead Plaintiff Deadline: April 1, 2022
This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Shattuck securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with Shattuck's October 2020 initial public offering; and/or (2) between October 9, 2020 and November 9, 2021, inclusive.
Allegations against STTK include that: (1) the collaboration agreement with Takeda was not solid; (2) Takeda and Shattuck would "mutually agree" to terminate the collaboration agreement in essentially one year; (3) as a result, Shattuck would cease to receive any future milestone, royalty, or other payments from Takeda; and (4) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form-2?prid=24562&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: May 28, 2021 - November 26, 2021
Allegations against FENC include that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Astra Space Inc. f/k/a Holicity Inc. (NASDAQ:ASTR)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/astra-space-inc-f-k-a-holicity-inc-loss-submission-form?prid=24562&wire=1
Lead Plaintiff Deadline: April 11, 2022
Class Period: February 2, 2021 - December 29, 2021
Allegations against ASTR include that: (1) Astra cannot launch "anywhere"; (2) Astra significantly overstated its addressable market; (3) Astra overstated the effectiveness of its designs and reliability; (4) Astra significantly overstated its plans for diversification and its broadband constellation plan; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE : The Law Offices of Vincent Wong